Department of Toxicology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209-0470, USA.
Toxicol Appl Pharmacol. 2011 Mar 15;251(3):173-80. doi: 10.1016/j.taap.2011.01.013. Epub 2011 Jan 26.
We have previously reported that among the other death proteins, hepatic secretory phospholipase A₂ (sPLA₂) is a leading mediator of progression of liver injury initiated by CCl₄ in rats. The aim of our present study was to test the hypothesis that increased hepatic sPLA₂ released after acetaminophen (APAP) challenge mediates progression of liver injury in wild type (WT) and COX-2 knockout (KO) mice. COX-2 WT and KO mice were administered a normally non lethal dose (400 mg/kg) of acetaminophen. The COX-2 KO mice suffered 60% mortality compared to 100% survival of the WT mice, suggesting higher susceptibility of COX-2 KO mice to sPLA₂-mediated progression of acetaminophen hepatotoxicity. Liver injury was significantly higher at later time points in the KO mice compared to the WT mice indicating that the abatement of progression of injury requires the presence of COX-2. This difference in hepatotoxicity was not due to increased bioactivation of acetaminophen as indicated by unchanged cyp2E1 protein and covalently bound ¹⁴C-APAP in the livers of KO mice. Hepatic sPLA₂ activity and plasma TNF-α were significantly higher after APAP administration in the KO mice. This was accompanied by a corresponding fall in hepatic PGE₂ and lower compensatory liver regeneration and repair (³H-thymidine incorporation) in the KO mice. These results suggest that hindered compensatory tissue repair and poor resolution of inflammation for want of beneficial prostaglandins render the liver very vulnerable to sPLA₂-mediated progression of liver injury. These findings are consistent with the destructive role of sPLA₂ in the progression and expansion of tissue injury as a result of continued hydrolytic breakdown of plasma membrane phospholipids of perinecrotic hepatocytes unless mitigated by sufficient co-induction of COX-2.
我们之前的研究报告显示,在其他死亡蛋白中,肝分泌型磷脂酶 A₂(sPLA₂)是四氯化碳诱导大鼠肝损伤进展的主要介质。本研究旨在验证以下假设:即,在野生型(WT)和环氧合酶-2 敲除(KO)小鼠中,在乙酰氨基酚(APAP)挑战后释放的增加的肝 sPLA₂介导肝损伤的进展。WT 和 COX-2 KO 小鼠给予通常非致死剂量(400mg/kg)的乙酰氨基酚。与 WT 小鼠 100%的存活率相比,COX-2 KO 小鼠的死亡率为 60%,表明 COX-2 KO 小鼠对 sPLA₂介导的乙酰氨基酚肝毒性进展的敏感性更高。与 WT 小鼠相比,KO 小鼠在后期的肝损伤更严重,这表明 COX-2 的存在可减轻损伤进展。这种肝毒性的差异不是由于乙酰氨基酚的生物活化增加,因为 KO 小鼠肝脏中的 cyp2E1 蛋白和共价结合的¹⁴C-APAP 没有变化。在 KO 小鼠中,APAP 给药后肝 sPLA₂活性和血浆 TNF-α显著升高。同时,肝 PGE₂降低,肝再生和修复(³H-胸腺嘧啶掺入)代偿性降低。这些结果表明,由于缺乏有益的前列腺素,代偿性组织修复受阻,炎症反应无法得到缓解,导致 KO 小鼠的肝脏非常容易受到 sPLA₂介导的肝损伤进展的影响。这些发现与 sPLA₂在持续水解坏死肝细胞的质膜磷脂的情况下,在组织损伤的进展和扩大中发挥破坏作用的观点一致,除非 COX-2 充分共同诱导,否则这种破坏作用无法得到缓解。